AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm.
Under the terms of the agreement, AstraZeneca received a payment of $250 million from Cheplapharm.
AstraZeneca will receive further non-contingent payments equal to $150m during the first half of 2021.
The present value of all payments, totalling $400m, will be reported in AstraZeneca’s financial statements within Other Operating Income in the fourth quarter of 2020.
Atacand (candesartan cilexetil) is a selective AT1 subtype angiotensin II receptor antagonist that is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults.
Atacand Plus is indicated for the management of hypertension when candesartan or hydrochlorothiazide monotherapy is not sufficiently effective.
Atacand was developed in collaboration with Takeda Pharmaceutical Company.